The Federal Trade Commission has asked electronic cigarette makers NJOY, JUUL Labs, Logic Technology Development, Fontem U.S. and R.J. Reynolds Vapor Company to provide sales and advertising data and e-cigarette product characteristics so it can help policymakers and the public better understand the industry.

The FDA has given emergency use authorization to Quidel for its QuickVue At-Home COVID-19 test.

Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay has been reissued emergency use authorization by the FDA, allowing it to be used with the Azova COVID-19 Test Collection Kit.

Memic Innovative Surgery has received De Novo approval for its Hominis Surgical System, a minimally invasive robotically assisted surgical device used during transvaginal hysterectomy.

Merck's latest ad campaign for its HPV vaccine Gardasil is focusing on adults ages 27 to 45. Merck's previous advertising had been targeted to parents of adolescents and the new campaign will include broadcast, cable, syndication, social media and promotional placements in physician offices and pharmacies.

Novartis' new television commercial for its multiple sclerosis drug Kesimpta promises less drama for patients by reducing relapses. The campaign for the drug, which was approved by the FDA in August, also includes digital, print and social media.

Seven hospitals and health system leaders talked about the importance of having strong digital front doors and shared strategies on how to create one. Kevan Mabbutt, Intermountain Healthcare's chief consumer officer and senior vice president, said a digital front door must address the needs of patients and caregivers while providing the best digital experience, while Brad Fixler, vice president of marketing at UC Health, said a strong digital front door is critical because it helps patients research and determine where to receive appropriate care.

Dr. Lee Fraser, executive VP at Digitas Health, writing in The Drum about successful COVID-19 vaccination campaigns.

OraSure Technologies generated $62.9 million in revenues during its fiscal fourth quarter, up 27% from the previous year, due to demand for molecular sample collection devices.

Molecular diagnostic firm Diagenode has been bought by Hologic in a deal worth $159 million. "We are excited to put our strong cash flow to work to acquire Diagenode and further strengthen our diagnostics business," said Hologic President and CEO Steve MacMillan.